MedTrace Logo

iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)

NCT05495685 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2022-08-10

No results posted yet for this study

Summary

DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.

Conditions

Sponsors & Collaborators

  • Guangzhou Burning Rock Bioengineering Ltd.

    collaborator INDUSTRY

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Gang Jin, M.D. · Department of general surgery, Changhai Hospital

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05495685 on ClinicalTrials.gov